News J&J to "price responsibly", says CEO post Trump meeting Gorsky promises "transparency report" on pricing.
News J&J/AbbVie blood cancer drug gets fifth US indication Imbruvica approved in marginal zone lymphoma.
News Despite Trump price concerns, JP Morgan event anticipates M&... 2017 could be a bumper year for M&A - but Trump's price control threats dominate
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
